Virologic Response and Safety After Oral Administration of PF-07817883, a Novel SARS-CoV-2 Mpro inhibitor, in Nonhospitalized Adults With Symptomatic COVID-19
Sign up to read this post
Join Now
Previous
Previous
A Small Molecule Based Bispecific Antigenic Immunotherapy for the treatment of Dengue
Next
Next